Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 65,461 | 57,532 | 57,126 | 65,696 | 66,345 |
| Cost of Goods | 27,312 | 32,644 | 29,203 | 39,488 | 33,356 |
| Gross Profit | 38,149 | 24,888 | 27,923 | 26,209 | 32,989 |
| Operating Expenses | 161,461 | 157,281 | 31,623 | 134,176 | 35,946 |
| Operating Income | -123,000 | -131,749 | -3,497 | -107,480 | -2,601 |
| Interest Expense | 4,504 | 4,552 | 4,501 | 5,394 | 5,311 |
| Other Income | 177 | -15 | 557 | -217 | 434 |
| Pre-tax Income | -127,327 | -136,316 | -7,441 | -113,091 | -7,478 |
| Income Tax | -14,623 | -11,447 | -754 | -5,735 | -3,872 |
| Net Income Continuous | -112,704 | -124,869 | -6,687 | -107,356 | -3,606 |
| Net Income | $-112,704 | $-124,869 | $-6,687 | $-107,356 | $-3,606 |
| EPS Basic Total Ops | -2.15 | -2.38 | -0.13 | -2.37 | -0.08 |
| EPS Basic Continuous Ops | -2.15 | -2.38 | -0.13 | -2.37 | -0.08 |
| EPS Diluted Total Ops | -2.15 | -2.38 | -0.13 | -2.37 | -0.08 |
| EPS Diluted Continuous Ops | -2.15 | -2.38 | -0.13 | -2.37 | -0.08 |
| EBITDA(a) | $19,727 | $12,015 | $14,496 | $10,818 | $24,029 |